Selected article for: "academic medical center and additional testing"

Author: Buckner, Frederick S; McCulloch, Denise J; Atluri, Vidya; Blain, Michela; McGuffin, Sarah A; Nalla, Arun K; Huang, Meei-Li; Greninger, Alex L; Jerome, Keith R; Cohen, Seth A; Neme, Santiago; Green, Margaret L; Chu, Helen Y; Kim, H Nina
Title: Clinical Features and Outcomes of 105 Hospitalized patients with COVID-19 in Seattle, Washington
  • Cord-id: xzsbkh5i
  • Document date: 2020_5_22
  • ID: xzsbkh5i
    Snippet: BACKGROUND: Washington State served as the initial epicenter of the SARS-CoV-2 pandemic in the United States. An understanding of the risk factors and clinical outcomes of hospitalized patients with COVID-19 may provide guidance for management. METHODS: All laboratory-confirmed COVID-19 cases in adults admitted to an academic medical center in Seattle, WA between March 2 and March 26, 2020 were included. We evaluated individuals with and without severe disease, defined as admission to the intens
    Document: BACKGROUND: Washington State served as the initial epicenter of the SARS-CoV-2 pandemic in the United States. An understanding of the risk factors and clinical outcomes of hospitalized patients with COVID-19 may provide guidance for management. METHODS: All laboratory-confirmed COVID-19 cases in adults admitted to an academic medical center in Seattle, WA between March 2 and March 26, 2020 were included. We evaluated individuals with and without severe disease, defined as admission to the intensive care unit or death. RESULTS: One-hundred-five COVID-19 patients were hospitalized. Thirty-five percent were admitted from a senior home or skilled nursing facility. The median age was 69 years and half were women. Three or more comorbidities were present in 55% of patients, with hypertension (59%), obesity (47%), cardiovascular disease (38%) and diabetes (33%) being the most prevalent. Most (63%) had symptoms for 5 days or longer prior to admission. Only 39% had fever in the first 24 hours, whereas 41% had hypoxia at admission. Seventy-three percent of patients had lymphopenia. Of 50 samples available for additional testing, no viral coinfections were identified. Severe disease occurred in 49%. Eighteen percent of patients were placed on mechanical ventilation and the overall mortality rate was 33%. CONCLUSIONS: During the early days of the COVID-19 epidemic in Washington State, the disease had its greatest impact on elderly patients with medical comorbidities. We observed high rates of severe disease and mortality in our hospitalized patients.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • ace inhibitor and acute cardiac injury: 1, 2
    • ace inhibitor and acute kidney injury: 1, 2, 3, 4
    • ace inhibitor and admission prior: 1
    • ace inhibitor and admission time: 1
    • ace inhibitor and lung disease: 1
    • ace inhibitor and lung injury: 1, 2, 3, 4
    • ace inhibitor and lymphocyte count: 1
    • acute aki kidney injury and additional information: 1, 2, 3
    • acute aki kidney injury and admission prior: 1, 2, 3, 4, 5, 6
    • acute aki kidney injury and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute aki kidney injury and lung disease: 1, 2, 3, 4, 5
    • acute aki kidney injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute aki kidney injury and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute ards respiratory distress syndrome and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and living home: 1, 2
    • acute ards respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25